Harvard
Charlestown, Massachusetts, United States
Marcela Maus, M.D., Ph.D., is currently a Professor of Medicine at Harvard Medical School, the Paula O’Keefe Chair in Oncology and Director of Cellular Immunotherapy at The Krantz Family Center for Cancer Research, Massachusetts General Hospital, an Attending Physician in the Hematopoietic Cell Transplant and Cell Therapy division of Oncology at MGH. She is an Associate Member of the Broad Institute of Harvard and MIT, and an Associate Member of the Ragon Institute of MGH, MIT, and Harvard.
Dr. Maus is internationally known for her work as a translational physician-scientist in the field of immunology, particularly as it relates to T-cell immunotherapies and cellular therapies in the treatment of cancer. Her laboratory focuses on the biology of human T cell activation, costimulation, and memory, and on the application of human T cell therapies to human disease, including forward and reverse translation of engineered T cell therapies in early-phase clinical trials. She has authored over 100 papers indexed in Pubmed and holds multiple NIH R01 grants and several Investigational New Drug Applications (IND’s).
Dr. Maus completed undergraduate studies at Massachusetts Institute of Technology (MIT) and holds graduate degrees (M.D., Ph.D.) from University of Pennsylvania. Dr. Maus trained in internal medicine at University of Pennsylvania and in hematology and medical oncology at Memorial Sloan Kettering Cancer Center.
Saturday, October 25, 2025
2:45 PM – 3:15 PM Central Time
Disclosure(s): 2SeventyBio: Equity interest (Ongoing), Officer or Board Member (Ongoing); A2Bio (SAB): Consultant (Ongoing); Adaptimmune: Consultant (Ongoing); Affyimmune: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); BMS: Consultant (Ongoing); Cabaletta Bio (SAB): Consultant (Ongoing); Cargo (SAB): Consultant (Ongoing); In8bio (SAB): Consultant (Ongoing); Kite Pharma: Grant/Research Support (Ongoing); KSQ: Consultant (Ongoing); Lumicks: Consultant (Ongoing); Moderna: Grant/Research Support (Ongoing); Sobi: Grant/Research Support (Ongoing)
Saturday, October 25, 2025
3:15 PM – 3:30 PM Central Time
Disclosure(s): 2SeventyBio: Equity interest (Ongoing), Officer or Board Member (Ongoing); A2Bio (SAB): Consultant (Ongoing); Adaptimmune: Consultant (Ongoing); Affyimmune: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); BMS: Consultant (Ongoing); Cabaletta Bio (SAB): Consultant (Ongoing); Cargo (SAB): Consultant (Ongoing); In8bio (SAB): Consultant (Ongoing); Kite Pharma: Grant/Research Support (Ongoing); KSQ: Consultant (Ongoing); Lumicks: Consultant (Ongoing); Moderna: Grant/Research Support (Ongoing); Sobi: Grant/Research Support (Ongoing)
